Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2008

View Archived Issues

Neuroprotective mechanism of Gammagard Liquid shown in vitro

Silymarin improves learning and memory in experimental rats

Merck describes synthesis of dual AKT1/2 inhibitor for cancer treatment

Lexicon team discovers potent deoxycytidine kinase inhibitor

Tumor regressions seen with blinatumomab in non-Hodgkin's lymphoma patients

Alteration of NNRTI GW-8248X yields several leads

Opioid receptor antagonist GSK-982 reduces food intake in obese and lean rats

Novel agents for transplant rejection described in recent patents

New treatment options for diabetes disclosed in recent patent literature

Bayer submits MAA to EMEA for recombinant human thrombin

Recent Helix BioMedix patent reports new agents for skin lesions

Pilot study finds effect of tiagabine in alcoholism

Novacea and Transcept sign merger agreement

Orexo initiates phase II program for OX-914 in inflammatory airways diseases

Cosmo reports positive results from phase I clinical trial of CB-03-01 antiandrogen cream

Calabar receives equity financing for phase II study of physostigmine in dry mouth

WRAIR is to conduct a clinical trial of Hawaii Biotech's Dengue vaccine

Oncolytics to initiate phase II combination clinical trial of Reolysin in NSCLC

Preclinical studies show potential of CR-3294 in intestinal mucositis

7TM commences phase I/IIa TM-30339 for the treatment of obesity

Perstorp completes another acquisition

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...